These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9824784)

  • 1. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program.
    Nagai N; Ogata H; Wada Y; Tsujino D; Someya K; Ohno T; Masuhara K; Tanaka Y; Takahashi H; Nagai H; Kato K; Koshiba Y; Igarashi T; Yokoyama A; Kinameri K; Kato T; Kurita Y
    J Clin Pharmacol; 1998 Nov; 38(11):1025-34. PubMed ID: 9824784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
    Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
    Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
    Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
    Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
    Nagai N; Ogata H
    Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program.
    Chen R; Li J; Hu WW; Wang ML; Zou SL; Miao LY
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1111-23. PubMed ID: 24061864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus.
    Johnsson A; Höglund P; Grubb A; Cavallin-Ståhl E
    Cancer Chemother Pharmacol; 1996; 39(1-2):25-33. PubMed ID: 8995496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum.
    Hanada K; Nishijima K; Ogata H; Atagi S; Kawahara M
    Jpn J Clin Oncol; 2001 May; 31(5):179-84. PubMed ID: 11450990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of cisplatin in adult cancer patients.
    de Jongh FE; Gallo JM; Shen M; Verweij J; Sparreboom A
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):105-12. PubMed ID: 15127229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic-Toxicodynamic Modeling and Simulation of Cisplatin-Induced Acute Renal Injury in Rats: Effect of Dosing Rate on Nephrotoxicity.
    Fukushima K; Okada A; Sasaki K; Kishimoto S; Fukushima S; Hamori M; Nishimura A; Shibata N; Shirai T; Terauchi R; Kubo T; Sugioka N
    J Pharm Sci; 2016 Jan; 105(1):324-32. PubMed ID: 26852862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin.
    Zhang JS; Imai T; Otagiri M
    Arch Toxicol; 2000 Aug; 74(6):300-7. PubMed ID: 11005675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
    Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin pharmacokinetics and its nephrotoxicity in diabetic rabbits.
    Najjar TA; Saad SY
    Chemotherapy; 2001; 47(2):128-35. PubMed ID: 11173815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
    de Jongh FE; Verweij J; Loos WJ; de Wit R; de Jonge MJ; Planting AS; Nooter K; Stoter G; Sparreboom A
    J Clin Oncol; 2001 Sep; 19(17):3733-9. PubMed ID: 11533095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction.
    Morita-Ogawa T; Sugita H; Minami H; Yamaguchi T; Hanada K
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):559-566. PubMed ID: 32949266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
    Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
    J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.
    Urien S; Lokiec F
    Br J Clin Pharmacol; 2004 Jun; 57(6):756-63. PubMed ID: 15151521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
    Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
    Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
    Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
    Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
    Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
    Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.